Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315292 | 1.00 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3LMNASPR | |
| SCHEMBL22468569 | 1.00 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3LMNASPR | |
| SCHEMBL4218523 | 0.84 | SPR (0.47) | SPRDPP8DPP7SMN1; SMN2 | |
| SCHEMBL22468571 | 0.84 | ALDH1A1 (0.36) | CYP2D6KCNH2HRH3SPRPDK2 | |
| SCHEMBL28405306 | 0.84 | ATM (0.31) | — | |
| SCHEMBL572692 | 0.82 | CYP2D6 (0.39) | CYP2D6KCNH2HRH3LMNAEPHX2 | |
| SCHEMBL22468413 | 0.81 | SPR (0.35) | CYP2D6KCNH2HRH3LMNASPR | |
| SCHEMBL25341447 | 0.81 | SPR (0.35) | CYP2D6KCNH2HRH3LMNASPR | |
| SCHEMBL19874798 | 0.80 | SPR (0.33) | CYP2D6KCNH2HRH3LMNASPR | |
| SCHEMBL24766583 | 0.79 | HPGD (0.49) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | TEIJIN PHARMA LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| WO-2023171736-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | 帝人ファーマ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| EP-4215519-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | Teijin Pharma Limited (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-116075309-A | Vitamin D derivatives having cyclic amine in side chain | 帝人制药株式会社 | 2023-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | VDR, CYP2R1, CYP24A1 | CYP2D6 327/4885KCNH2 1563/4885HRH3 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.